"We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy."
"In the late 2000s, Eileen Faucher was a postdoctoral researcher at Columbia University in New York City, studying immuno-oncology and nanotechnology. She was drawn to the intersection of science and business, or working in business development - informing a company's strategic decisions about which therapies to pursue - so she decided to transition to the drug-development industry. Through networking, she landed a job at Dendreon, a pharmaceutical company in Seattle, Washington, specializing in cancer immunotherapies."
A postdoctoral immuno-oncology researcher transitioned into pharmaceutical competitive intelligence, joining Dendreon and later founding Brass Tacks Insights in Seattle. The firm gathers and analyzes information about competitors, customers and the broader market to inform strategic decisions for drug developers. Services include assessing current and projected standards of care, forecasting treatment landscapes five to eight years ahead, and advising on study design and regulatory pathways. Rapid changes in oncology guidelines and accelerated approval routes make it challenging to design trials that remain clinically meaningful when results report years later. A team of PhD consultants helps companies prepare for shifting landscapes to bring treatments to patients.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]